profit from every $100 of sales.
$0$100
Alvotech
$0.28-1.96% today
-81.6% in 1 year
1-year low $0.151-year high $1.95
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Alvotech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Alvotech | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Alvotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- 10.6×
- 0.08
- -4.0×
- 1.9×
- –
- –
- -203.9%
- -7.1%
- 0.0%
Profitability
- 61.4%
- 13.8%
- -14.4%
- -7.0%
- -11.7%
- -130.6%
- 35.2%
- -5.7%
- 6.6%
- 30.5%
Growth
- +99.8%
- –
- +61.0%
- –
- +72.9%
Financial health
- -35.6×
- -5.16
- 102.5%
- 0.5×
- 1.76
- 0.88
- 0.39
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 19%of 964
Top 43%of 898
Top 5%of 911
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.09 | -0.05 | −91.5% |
| Mar 18, 2026 | 0.01 | -0.01 | +239.8% |
| Nov 12, 2025 | -0.02 | -0.03 | +34.7% |
| Aug 13, 2025 | 0.11 | -0.05 | +330.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
22No pass
Philip Fisher
41No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
32No pass
Terry Smith
36No pass
Questions about Alvotech
Is Alvotech a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Alvotech AI analysis
What does Alvotech do?
Alvotech Holdings SA, through its subsidiaries, develops and manufactures biosimilars for global markets. The company is based in Iceland. It is in Drug Manufacturers - Specialty & Generic.
Does Alvotech pay a dividend?
No. Alvotech does not pay a dividend at the moment.
How has Alvotech stock done over the past year?
Down 81.6% over the past twelve months, to $0.28. It traded between $0.15 and $1.95 and is 85.9% below its high.
Who are Alvotech's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Alvotech's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.